Novartis AG Common Stock (NY:NVS)

141.00 -0.05 (-0.04%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

59 60 Next >

Novartis Earns Near-Best Overall Rating As Profit Growth Climbs ↗

March 05, 2025

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Via Investor's Business Daily

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases. ↗

March 04, 2025

Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction ↗

March 04, 2025

Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.

Via Investor's Business Daily

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy ↗

March 03, 2025

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

Via Benzinga

3 Dividend Stocks That Are No-Brainer Buys Right Now ↗

March 01, 2025

Via The Motley Fool

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program ↗

February 26, 2025

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech.

Via Benzinga

Is the Market Bullish or Bearish on Novartis? ↗

February 26, 2025

Via Benzinga

Uncovering Dividend Opportunities with NYSE:NVS. ↗

January 27, 2025

Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS).

Via Chartmill

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗

February 24, 2025

Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...

Via Benzinga

This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday ↗

February 13, 2025

Via Benzinga

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal ↗

February 11, 2025

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio.

Via Benzinga

Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight ↗

February 07, 2025

A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads.

Via Benzinga

Topics Artificial Intelligence

Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them ↗

February 10, 2025

The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads.

Via Benzinga

2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond ↗

February 03, 2025

Via The Motley Fool

Novartis Ag (NVS) Q4 2024 Earnings Call Transcript ↗

January 31, 2025

NVS earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading ↗

January 31, 2025

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.

Via Stocktwits

Topics Intellectual Property

Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker ↗

January 31, 2025

The company's biggest moneymaker is expected to face off with lower-cost generics this summer.

Via Investor's Business Daily

Topics Earnings

US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact ↗

January 31, 2025

US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings.

Via Benzinga

Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries ↗

January 31, 2025

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025.

Via Benzinga

Topics Earnings Intellectual Property

When you look at NYSE:NVS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

January 31, 2025

NOVARTIS AG-SPONSORED ADR is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:NVS showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Earnings Scheduled For January 31, 2025 ↗

January 31, 2025

Via Benzinga

AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings? ↗

January 30, 2025

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Via Benzinga

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗

January 29, 2025

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Via Benzinga

Topics Government

AI Pharma: 2 Paths to AI-Powered Drug Investment

January 28, 2025

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Via MarketBeat

Topics Artificial Intelligence

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases ↗

January 22, 2025

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Via Benzinga

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug ↗

January 16, 2025

Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.

Via Benzinga

Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

January 10, 2025

Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development ↗

January 08, 2025

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Via Benzinga

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗

January 06, 2025

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.

Via Benzinga

Topics Lawsuit

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.